text:
TCR Forgotten Pulitzer Series: Lamb in His Bosom (1934)
The Committee Room begins its look at now mostly forgotten Pulitzer Prize winning fiction with 1934 winner Lamb in His Bosom by Caroline Miller. The story of a pioneer family, the Carvers, scratching out lives in the "pineywoods" of southwest Georgia in the decades before the Civil War, Lamb in His Bosom is a richly detailed, often poetically written account of ordinary people struggling for survival. Georgia-born Miller, a young wife and mother at the time she wrote Lamb, based the story in part on her own forebears and she makes it clear that the cliched trappings of the Antebellum south -- hoop skirts, cotillions, plantations, and especially slaves -- played no role in lives of the Carvers and other plain folks like them.
In its opening chapters Lamb seems to be offering up a plot, particularly when the Carvers' restless son Lias returns from a trip to "The Coast" -- a distant, exotic place that the menfolk occasionally visit in order to trade -- with a city-bred wife, Margot, who seems unsuited for the hardships of backwoods life. Margot, however, quickly settles in and the novel plays out as a cycle of births and deaths in the Carver family as the decades pass with the focus on the Carver family's daughter, Cean.
"Lamb in His Bosom is written in the tradition of historical realism, which readers of today may find rather slow and overly detailed," literary scholar Emily Wright told TCR. "On the other hand, Miller's lyrical descriptions of a woman's life lived close to nature, both internal and external, do stand the test of time, I think, and have the potential to be profoundly moving and meaningful even to contemporary readers. Also, the novel retains its value as a historical document, being one of the few works available that describes, with remarkable accuracy, a group of southerners whom most readers know nothing about: nonslaveholding white pioneers."
Published in late 1933 and mostly well-received by critics, Lamb in His Bosom initially sold well only in the South. Its popularity went nationwide after it was awarded the Pulitzer Prize in May 1934. Lamb was second on the Publisher's Weekly bestseller list of 1934, surpassed only by another now mostly forgotten novel, Hervey Allen's Napoleonic-era adventure Anthony Adverse.
Wright points out that Joseph Pulitzer's will required that the award be given to novels that "best represent the whole atmosphere of American life" and that in the 1930s "the award tended to go to works that displayed typical American life and also to works that achieved significant popularity with the American reading public." She notes that three other Southern novels won the Pulitzer during the Depression years -- T.S. Stribling's The Store (1933); Margaret Mitchell's Gone With the Wind (1937); and Marjorie Kinnan Rawlings' The Yearling (1939). "In my analysis," Wright says, "this signifies that whereas throughout most of American history, the South has been looked down upon for being ignorant, poor, and bigoted, during a time of economic hardship the nation looked to the South for models of endurance and recovery."
(courtesy of University of Georgia)
Caroline Miller, who died in 1992, published just one other novel, Lebanon (1944). The story of a backwoods girl much like Cean Carver in Lamb, Lebanon flopped with both critics and book buyers. Miller blamed its failure on cuts made by editors because of the paper shortage during World War II but Wright says it is unlikely that Lebanon would have done well even if it had not been cut -- "The Depression era was receptive to a homespun tale of struggle and survival in the form of Lamb in His Bosom. By the 1940s that appeal had faded. [Also] the novel is rather melodramatic in some respects. And finally, the popularity of historical realism was waning by the time this book came out."
Miller's final published work, the short story "Cricket," appeared in Ladies Home Journal in 1945.
"In the mid-forties," Wright says, "Miller underwent the first of several lengthy hospitalizations for what appears to have been some combination of mental and physical collapse. While the nature of her health problems remains unclear, she apparently was unwell to some extent throughout the remainder of her life. Miller did continue to write, as her papers in the Emory University archives are full of drafts of stories, novels, and screenplays...from what I have read, they seem to be very vague and formless and incomplete."
Originally published by Harper and Brothers, Lamb in His Bosom has been available since 1993 by from Peachtree Publishers.
Peachtree edition
"Lamb in His Bosom came to my attention through Celestine Sibley, writer, reporter and beloved columnist at the Atlanta Journal-Constitution," explained Margaret Quinlin, Peachtree Publishers president, to TCR. "Celestine had been invited to speak at an event honoring the publication of Lamb in His Bosom in Baxley, Georgia, Caroline Miller's hometown, in 1991. She wrote a column about her visit and how much she loved the book. She was distraught to discover that it was unavailable from the publisher, especially because it was the first work of fiction by a writer from Georgia to receive the Pulitzer Prize...Celestine encouraged me to read the book and I did. I loved it too. It reminded me of Growth of the Soil, a novel that I had loved by the Norwegian writer Knut Hamsun."
Quinlin was put in contact with Caroline Miller's son, Bill Miller, who was eager to see his mother's bestseller back in print. Bill Miller cleared the way for a reversion of rights from Harper, which had long neglected Lamb, to Peachtree. The contract was signed in the summer of 1992, just before Caroline Miller's death. "I believe she had been told that a new edition was forthcoming," Quinlin says.
Quinlin notes that the Pulitzer Prize "made a great difference" in Peachtree's decision to publish Lamb. "The market for literary fiction is challenging on many levels including reaching the audience with the right message about a book," explains Quinlin. "This challenge is magnified on the re-release of a work published decades ago. The Pulitzer label signals quality and increases the likelihood that the book will be mentioned in lists and reviews as well as included in library book purchases."
Following Pulitzer (interesting and thorough blog examining all Pulitzer fiction winners)
20th-Century American Bestsellers (superbly detailed University of Illinois database)
Georgia Women of Achievement
Georgia Writers Hall of Fame
New Georgia Encyclopedia
Posted by tvmoviefan at 1:30 PM
Labels: Caroline Miller, Emily Wright, Fiction., Lamb in His Bosom, Pulitzer Prize, TCR Forgotten Pulitzer Series
Thanks for the link, especially since my review was far less kind (and more than a little bit snarkier) to Miller's work than you were. I definitely appreciated seeing the take you took on the novel, and the added information about Miller's life is definitely interesting. I wish I felt she'd been as successful in her writing as you do, but I can't deny there were moments when she really had me under her spell. I'm intrigued by this "forgotten Pulitzer" series, and will definitely be back to see where it takes you. :-)
ellathomas121 August 6, 2018 at 3:01 AM
The article you have shared here very awesome.
Ella Thomas
Large Group Rental Mexico
Mexico Vacations
Wonderful review of a wonderful book. However, I did notice an error: Ms. Miller was from Waycross, not Baxley. She did move to Baxley in her late 20s and spent much of her life there, though.
very nice series for read XD agen togel terpercaya
vedic villege Escort
vedic villege Escorts
vedic villege Escort service
vedic villege Escort girls
vedic villege call girls
vedic villege independent Escorts
vedic villege independent Escort
VILLAGE CALL GIRLS
VILLAGE CALL GIRL
KOLKATA FEMALE ESCORTS
KOLKATA HOTEL ESCORTS
KOLKATA MODEL ESCORTS
KOLKATA CALL GIRL
KOLKATA CALL GIRL SERVICE
CALL GIRL SERVICE
KOLKATA INDEPENDENT CALL GIRLS
KOLKATA INDEPENDENT CALL GIRL
TCR Literary Journal Series: Bellingham Review
TCR Story of the Month for April: "King of the Ape...
TCR Forgotten Pulitzer Series: Lamb in His Bosom (...
Poetry Podcasts for National Poetry Month
Books That Changed America
Top Writers Read Their Favorite Story Written by A...


PELLA, Iowa (AP) — The Cleveland Cavaliers' Kyle Korver joined his two remaining brothers in comforting their parents during a funeral for their youngest brother.
The Des Moines Register reports that Kyle Korver stood Monday at a church in Pella, Iowa, with his brothers Klayton and Kaleb and told their parents that life without Kirk will be different but "You will always have four sons."
Cavs spokesman B.J. Evans says Kyle Korver won't be with the team for a game Tuesday night against the Heat in Miami.


text:
Lindsey Graham Hints William Barr Could Reopen Hillary Clinton Investigation
Barr could investigate potential political bias in Clinton campaign
By: Daniel Chaitin |@NeonNettle
on&nbsp1st April 2019 @ 4.00pm
Sen. Lindsey Graham, R-S.C., said he knows Barr 'pretty well' and he is 'pretty upset'
Sen. Lindsey Graham, R-S.C., has suggested that Attorney General William Barr could reopen the investigation into Hillary Clinton's unauthorized private email server.
Graham, chairman of the Senate Judiciary Committee, told Fox News that he hopes Barr will appoint a special counsel to investigate potential political bias.
"So it seems to me that she was interviewed not under oath. She had a couple of her staff people with her. People in her campaign were given immunity without anything in return. Nobody in the Clinton investigation went to jail for lying about the process because there was no process," Graham said.
"I know Bill Barr pretty well, and he's pretty upset about the way all this was handled," he added.
"I don't know if he's going to have a special prosecutor to look at the probability of criminal misbehavior," Graham said.
Fired FBI Director James James Comey was responsible for overseeing his agency's inquiry into the unauthorized email server
[RELATED] Lindsey Graham Vows to Investigate McCabe, Rosenstein Coup Against Trump
"I'm going to look at what happened from an oversight role. But I hope there's a special counsel appointed to look at DOJ corruption and political bias, you know? Because Mueller did his job against Trump. Nobody's really looked at the Clinton campaign, the FISA warrant abuse or the counterintelligence investigation for criminality yet and somebody should."
"I'm not so much worried about retrying her, but I want to make sure that the public understands that she got away with something they wouldn't get away with," he said.
"I think it's important to understand that political bias probably drove the Clinton outcome, not the facts. I really don't believe that Comey just took over the investigation from [former Attorney General Loretta] Lynch based on a tarmac meeting. I just want the American public to know that the standard used against Clinton is an outlier."
It's not the way business is done. And why did they choose that path? I think they had a political bias."
"They wanted Clinton to win, Trump to lose. And here's the point. How could she win if the Department of Justice indicted her? I think that's what drove the decision not to indict. They wanted her to win."
Fired FBI Director James James Comey was responsible for overseeing his agency's inquiry into the unauthorized email server Clinton used.
In July 2016, Comey declared that his agency would not recommend criminal charges against anyone involved with Clinton's private email network, despite finding members of Clintons' team was "extremely careless" in handling classified emails.
But according to the Justice Department's inspector general last year, Comey 'deviated' from the usual standard of practices of the agency when dealing with the Hillary Clinton classified email probe.
Despite the announcements, IG Michael Horowitz insists that Comey was more 'stupid' than malicious.
'While we did not find that these decisions were the result of political bias on Comey's part, we nevertheless concluded that by departing so clearly and dramatically from FBI and department norms, the decisions negatively impacted the perception of the FBI and the department as fair administrators of justice,' the report read.
Presdient Donald Trump repeatedly attacked the controversy surrounding Hillary's emails
Presdient Donald Trump repeatedly attacked the controversy surrounding Hillary's emails, even with his 2016 campaign the chant "Lock her up" becoming one of the driving forces behind his presidency.
According to a report from the Washington Examiner: A DOJ inspector general published last summer determined Comey was "insubordinate" and "affirmatively concealed" his plans from Justice Department leadership during the investigation into Clinton's private email server.
Although the report criticized FBI actions as unorthodox and at times improper, ultimately it concluded that this did not change the outcome of the Clinton email investigation.
"[W]e did not find documentary or testimonial evidence that improper considerations, including political bias, directly affected the specific investigative decisions discussed below, or that the justifications offered for these decisions were pretextual," wrote Inspector General Michael Horowitz.
Graham said during a Monday news conference that there would be resumed investigations into the origins of special counsel Robert Mueller's investigation and potential bias in the Justice Department and FBI, including a look at FISA warrants.
Barr shared a summary of Mueller's report to Congress last weekend that said Mueller's team found no collusion between the Trump campaign and Russia.
Mueller also failed to determine whether Trump obstructed justice, and Barr said he and Deputy Attorney General Rod Rosenstein decided there was insufficient evidence to show the president committed a crime.
While Trump and his allies claim he is exonerated, Democrats who are unsatisfied with the summary are requiring to see the full report immediately by next week.
Barr said last week he expects a redacted version of Mueller's report to be released in mid-April, "if not sooner."
The attorney general also volunteered to testify publicly after Mueller's report is issued to the public and said he is available to appear before the Senate Judiciary Committee on May 1 and the House Judiciary Committee on May 2.
[RELATED] Lindsey Graham Calls For Investigation Into FBI's Handling Of Hillary Clinton
tags: Hillary Clinton | FBI
Attorney General Launches Investigation of FBI's 'Treasonous Acts' Against Trump
William Barr confirms he's already assembled a team to probe anti-Trump bias 10th April 2019 @ 3.00pm
FBI Continued Using Steele Dossier, Despite Noting Anti-Trump Bias, Docs Show
Unverified document was used for multiple FISA applications after red flags noted 10th August 2019 @ 1.00am
President Trump Shreds 'Current' FBI Director: 'He Will Never Be Able To Fix The FBI'
FBI Director Christopher Wray response to the IG report is called out 10th December 2019 @ 6.00pm
Lindsey Graham Says FBI Probe Into 'Russia Collusion' Became 'Criminal Pretty Quick'
Senator weighs in on highly anticipated IG report 10th December 2019 @ 8.00pm
Top Forbes Journalist: 'Corrupt FBI And DOJ All Lead Back To Obama'
Del Beccaro says claims that the biased FBI and DOJ Officials broke the law 10th February 2018 @ 4.02pm
10th April 2019 @ 3.00PM
10th August 2019 @ 1.00AM
10th December 2019 @ 6.00PM
10th February 2018 @ 4.02PM

redpajama_set_name: RedPajamaCommonCrawl


text:
Cancer Support In France
Updated April 2014
In the summer of 2000, after two years of planning, Linda Shepherd and her husband, Andrew, arrived in France. They had bought a lovely old house and were excited about their new life ahead of them.
Almost immediately, though, their dreams were dealt a cruel blow. Three months after arriving, a routine doctor's appointment for a HRT prescription ended with Linda being diagnosed with breast cancer. The news was all the more shocking because it was so unexpected. 'The doctor had sent me for a mammogram because I'd been on HRT for three years and he wanted to be on the safe side,' says Linda. 'There was no inkling of a problem so when I went to have the mammogram I went on my own. Afterwards I planned to go to the garden centre.'
Linda did make it to the garden centre but she didn't buy any plants. 'For two hours I wandered about in a shell-shocked haze,' she says. The mammogram had swiftly been followed by an echograph for a further examination of Linda's breasts, which resulted in the diagnosis of cancer. 'The specialist pointed out an area of shadow in my left breast and told me it was cancer,' says Linda. 'He told me to tell my doctor that I had to get rid of it immediately.'
The emotional trauma of the diagnosis was intense, made even more overwhelming by the fact that Linda, just 48 then, had left a stressful job as a secondary school teacher for a happier life with Andrew in France. 'All your plans just turn to dust,' she says. 'I remember going for a walk with the dogs one day and sobbing my heart out thinking, 'I don't want to die.'
The next few weeks were like 'being on a rollercoaster.' The initial diagnosis made in October was quickly followed by a lumpectomy to remove the diseased tissue. 'Before the operation they told me that if the biopsy showed that it was definitely cancer, they would remove some of the lymph nodes under my arm to check how far it had spread,' says Linda. 'As soon as I came round I could feel the tightness under my armpit, and I knew I had cancer.'
Thankfully the disease had not spread to the lymphatic system, but a mastectomy was needed. This was carried out a week after the lumpectomy. Radiotherapy followed in the New Year. While Linda coped well with the initial treatment, even the mastectomy, the radiotherapy was a different story. 'The diagnosis and initial treatment had been a positive experience,' she says. 'Everything had been done so professionally and so quickly. But the radiotherapy was incredibly gruelling and the aftermath of it was emotionally horrific.'
The radiotherapy consisted of several short doses of radiation, five days a week for five weeks. Linda's travelling time to the hospital was an hour each way. 'Half way through the first week I started to experience pain like I had never experienced before,' she says. Centred round her ribcage, the sheer physical force of the pain triggered a psychological trauma that manifested itself in panic attacks that left her unable to move. In the end, she elected to spend the last three weeks of her treatment in the psychiatric section of the hospital.
It was now, while she was struggling to cope, that Linda really needed to talk to someone who understood what she was going through – and in English. As she discovered, while it was difficult expressing her emotions in English, trying to do so in a second language when her vocabulary was limited was almost impossible. 'Also the fear makes it very hard to understand what is being said to you in your second language, even if you are moderately competent,' she continues. 'Words simply don't register with you.'
Linda contacted Breast Cancer Care in the UK and was able to find the support she needed, but her experience made her wonder how others in France coped both emotionally and practically. 'While some of the doctors spoke English, all my psychological support was in French,' says Linda. 'I was okay because I had studied the language for two years in night-classes but I began to ask myself what it must be like for someone who could barely speak the language. How would they feel? It is already a stressful time, but not to be able to fully understand what is going on would make the situation even worse.'
Three years later, with her cancer in remission, Linda set about changing things. Her research amongst the medical professionals treating her showed that, understandably, there was no support for English-speaking people affected by cancer in France – so, with their full support, in 2003 she and a group of like-minded people who lived in the Charente started 'Cancer Support in the Poitou-Charentes'. In 2006 the association changed its name to 'Cancer Support France' to reflect the fact that today the registered charity helps people from all over the country. Well-respected amongst the French medical profession, CSF is also supported by Macmillan in the UK, who regularly come to France to train CSF volunteers.
Today there are 15 CSF associations across France, each one affiliated to CSF National. Although every CSF association shares the same aims and has similar statutes, each is organised slightly different according to the needs of its local members, its trained volunteers and the way of life in that particular part of France.
The CSF associations support everyone touched by cancer, not only the patient, and many of the clients are family members or carers. All volunteers who have direct contact with clients must follow a training programme which is identical in every association. They must also attend continuing training to ensure that the skills acquired are constantly practised. As a result, the support provided through CSF anywhere in France is of the same high standard. For those who do not feel able to ask for support by telephone, there is a CSF Forum which has lots of useful information and documents, some of which have been translated into English. These can also be found on the CSF National website which has details of every affiliated CSF association.
One of CSF's main roles is to give people information on the disease and its treatment. 'Cancer robs patients and their families of control,' says Linda, pictured left. 'If you can give them an element of control back, by helping them find the information they need or formulate the questions they need to ask their specialists, they can begin to walk along this very dark path.'
The charity tries to provide bi-lingual speakers who can attend consultations with patients. Most importantly it also provides someone to talk to, whether face to face, on the phone or by email. It is this latter form of help that Frances Rosemont has needed.
Frances, age 64, was diagnosed with breast cancer in January 2004. She and her husband David, 61, had been married for three years and were planning to move to Brittany for his retirement when she was told her cancer was incurable but controllable. 'It was horrendous,' says Frances. 'We dealt with it because we're quite good at dealing with things but it was a blow to our imaginings of life's future. I was very angry. There was a lot of 'why me?' over and over again. But you have keep chucking that thought out and get on with life. We came to France because we wanted to make the most of what time we have left, and don't regret it one bit. Quite the reverse.'
The day after she arrived Frances saw a GP, and three days after that she had started chemotherapy. Since then she has had 30 sessions of the treatment but is now awaiting medication that is currently undergoing trials in America. 'I first called CSF when I was at a very low point,' she says. 'I've spoken to Linda now for the past two years. Because she has had cancer herself she knows what you are going through and how that makes you feel.
'I call when I am in a panic and I always feel a lot calmer afterwards. She tells me to hang on in there and you need people to say that to you to keep you going. And you can tell her things that you would not want to tell your friends or family. We have a strong rapport and that is very important.' This is despite the fact that Frances and Linda have never met in person.
CSF also provides support for the family of people affected by cancer. 'They are the forgotten ones,' says Linda. Frances husband, David, first contacted the charity without telling his wife. 'I am not naturally someone who begs for counselling,' says David. 'I'm one of those 'true Brits' who has been taught not to show emotion, but when someone you love has cancer they, and you, are in incessant emotional turmoil. You need help to come to terms with it. For me, it was about straightening my head out, to know what was going on and understand it, so I could help Frances too.'
Being able to talk to someone at CSF also gives both David and Frances a chance to have a more normal life. 'With cancer it is easy for it to become the number one subject which is not helpful,' says David. 'It's good to be able to talk to someone else about it, and then for the two of us to live our daily life.'
GETTING IN CONTACT WITH CSF
Telephone Help-line: 1810 240 200. This is an answerphone and someone will be in touch within 24 hours.
E-mail Help-line: [email protected] Again, someone will respond within 24 hours.
CSF website: www.cancersupportfrance.org
CSF Forum: www.csf-forum.org
Cancer Support France is run entirely by volunteers and is always looking to welcome new faces. For an informal chat and further details contact your nearest CSF association or, if there isn't one near you, CSF National.
UPDATE APRIL 2014:
A long-awaited need has been filled, the Tarn now has its own cancer support group as part of CSF Sud de France. They are there to offer advice and support to anyone in the Anglophone community who is touched by cancer, whether it is as a patient, friend, family or bereaved. You do not have to be British to benefit, all English speaking people are welcome.
If you are interested and would like more information, need help or advice or would like to join in any capacity, please look at the web sites below. My main object at the moment is to spread the word in the Tarn, we especially need members in the south and east of the department. If you think you can help by distributing leaflets to your local doctor's surgery, hospital, pharmacy or anywhere else appropriate, or can help in any way please contact Helene, tel: 0563349401
CSF Sud de France local site:
www.csf-suddefrance.webs.com
the CSF National site:
www.cancersupportfrance.org
For further information about CSF Sud de France please contact Penelope:
Our Help Line is : 0468690137
Exclusive Healthcare
Exclusive Healthcare specialises in health insurance for English speaking residents in France. We offer a range of policies designed to meet the needs of people moving to France at every stage and in all circumstances. From private policy to Health top up cover in France. We are more than an insurer, we are a helping hand. Find out more
SwissLife
At Swisslife we provide health insurance for expats in France whether you are entitled to the French health system or not. We also provide banking, travel, home, car and motorbike insurance. 60% of our business is through recommendation and we are very proud of that.
Insurance Agent for English Speakers in France
AXA Insurance: helping you every step of the way. Insurance, healthcare, life assurance, retirement planning, investments, & banking.


text:
Q: How to transpose Excel Pivot table I have source table where I have every number category in separate column (something like already pivoted).
I would like to create pivot table, where division are in columns and number category in rows.
I need to transpose columns with rows from this layout:

to something like this:

Is it possible within standard pivot without Power query and unpivoting my data? (I guess with PQ it would be bigger and took longer to refresh).

A: In the pivot field pane, drag Values from the Columns box to the Rows box, and drag Divisions from the Rows box to the Columns box.

redpajama_set_name: RedPajamaStackExchange


text:
Double Feature of Films "Dream Big" and "Spare Parts" at New Canaan Library Highlights the Impact of Human Ingenuity and Technology
« Meditation Open House
Family Day of Exploring Art Together »
New Canaan Library's One Book New Canaan town wide read of Joshua Davis's Spare Parts has been underscored with numerous events throughout the month of March. On Saturday, March 23 the Library will offer a special double feature of two films involving technology and engineering, both which figure strongly in Spare Parts. Learn how engineering is not only a vital part of our lives, but an exciting, innovative field that creates more and more man made marvels. Dream Big: Engineering Our World will be shown in the Adrian Lamb Room at 1 p.m., followed by the feature film Spare Parts. Please register for this event, online at newcanaanlibrary.org.
Narrated by Academy Award winner Jeff Bridges, Dream Big examines man-made marvels that will forever transform the way you think about engineering. From the Great Wall of China and the world's tallest buildings to underwater robots, solar cars, and smart, sustainable cities, Dream Big celebrates the human ingenuity behind engineering, and shows how engineers push the limits of innovation in unexpected and amazing ways.
Based on the true events, Spare Parts tells the uplifting story of four undocumented teenagers who, against all odds, and under the guidance of exceptional teachers, harness their interest in
technology to fight for a chance to compete at a prestigious robotics competition. Despite an underfunded school system and the struggles of living in a hostile environment, this team of inspired young men use determination and ingenuity to not only defy the odds but to excel.
New Canaan Library Event
New Canaan Public Library
https://newcanaanlibrary.org/event/movies-ncl-dream-big-spare-parts/
cchumney@newcanaanlibrary.org
newcanaanlibrary.org
Traditional Mexican Music and Dance Performance is Finale for Library's 2019 One Book New Canaan
Night of 1,000 Fireflies at New Canaan Nature Center


text:
First Look at 2017 Chargers Depth Chart
As the Los Angeles Chargers get set to kick off the preseason Sunday against the Seattle Seahawks, the team released the first unofficial depth chart of 2017.
As a reminder, fans shouldn't look too much into the unofficial depth chart as it is merely nothing more than a piece of paper at this point.
"The depth chart doesn't mean much right now," Head Coach Anthony Lynn said. "It's something that we're working through, and we'll keep working through it as we evaluate the guys. There is a lot of competition going on all throughout the roster, so it will keep evolving."
Still, here are some topline items that stand out:
With Jason Verrett practicing but not listed on the depth chart, second-year cornerback Trevor Williams gets the nod at starting CB.
The battle to backup Melvin Gordon has been a good one throughout camp, and according to the depth chart Branden Oliver will get first crack at it as he is listed second behind number 28. Andre Williams is third while Kenjon Barner is fourth.
A pair of undrafted free agent linebackers are listed in the second group in James Onwualu and Nigel Harris.
Dwight Lowery and Tre Boston have split reps at starting free safety throughout camp, but the incumbent is listed with the starters.
Dan Feeney is listed twice with the second team at guard and center.
Russell Okung is the only new addition added this offseason currently listed with the first team.
Relive the Chargers Top Offensive Plays of the Season
Take a look at the Bolts Top 10 plays on offense from the 2021 season plus some honorable mentions.
Three Takeaways: Derwin James Can't Wait for Bolts to 'Come Back Stronger'
Here's what Chargers safety Derwin James had to say during his end of season press conference.
Beat Writers Roundtable: 2021 Chargers MVP
This pick was unanimous.
10 Insights from Justin Herbert's Second NFL Season
Herbert set the Chargers' single-season record for passing touchdowns, passing yards and completions.


Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. The Battle of Leuven was fought in September 891 between the Franks and the Vikings, essentially ending the Viking invasions in the Low countries. The existence of this battle is known due to the Annales Fuldenses. The Frankish force was led by Arnulf of Carinthia. The Franks successfully repelled the Viking assault and it is reported that the bodies of dead Northmen blocked the run of the river (ita ut cadaveribus interceptum alveum amnis siccum appareret).


Robin Piper trained as a social worker at the London School of Economics. He has worked in child and adult psychiatry and later specialised in Family Therapy at the Marlborough Family Service. He went on to train as a psychotherapist with the British Association of Psychotherapists, and the London Centre for Psychotherapy. For several years he was the co-conductor of the large group at the Institute of Group Analysis with Patrick De Mare.


text:
http://midamir.com/wp-content/themes/midamir/
http://midamir.com/
#26ade4
info@midamir.com
1501 Venera Ave Suite 225 Coral Gables, FL 33146
Traditional IR
Digital IR
Online Presence / Marketing
You are here: Home » Disclaimer
INVESTORS SHOULD READ THIS DISCLAIMER
Who owns and controls the website located at http://MIDAMir.com
The website located at http//www.MIDAMir.com (the Website) is owned by MIDAM Ventures LLC., a Florida corporation. The Website, its owner, affiliates, control persons, directors, officers, employees and agents are hereafter collectively referred to as the "Publisher", "we", "us" or "ours".
We are paid advertisers, also known as stock touts or stock promoters who disseminate favorable information (the "Information") about publicly traded companies (the "Profiled Issuers").
How is the Information published?
We publish the Information on the Website, in newsletters, audio, and live interviews featured reports message boards and email communications for specific time periods that are agreed upon between us and the Profiled Issuer. Our publication of the Information is known as a "Campaign".
Will everyone receive the Information at the same time?
No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart.
How is a potential investor impacted if they receive the Information later than other investors?
If the trading volume and price of a Profile Issuer's securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.
What will happen when the Campaign ends?
Most, if not, all of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide variations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will likely lose most, if not, all of their investment.
Why do we publish only favorable Information?
We only publish favorable information because we are compensated to only publish favorable information.
Why don't we publish negative information?
We don't publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information.
Is the Information complete, accurate, truthful or reliable?
The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one sided and not balanced, complete, accurate, truthful or reliable.
What we do not do.
We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence or research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers' financial condition, operations, business model, management or risks involved in the Profiled Issuer's business or an investment in a Profiled Issuer's securities.
The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission's Edgar database or other available public sources.
We have been informed that neither the chief executive officer nor the chief financial officer of the Profiled Issuer has reviewed, edited or otherwise approved the Information.
What will happen if an investor relies on the Information?
The Information is neither a solicitation to buy nor an offer to sell securities. The Information should not be used to make an investment decision or for trading or investment purposes. If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not, all of his or her investment.
Who pays us to publish the Information?
The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer's securities.
The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, "What we are compensated".
What warranties do we make about the Information?
None. We make no warranty or representation about the Information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
Who is responsible if an investor relies on the Information?
The investor. We are not responsible or liable for any person's use of the Information or any success or failure that is directly or indirectly related to such person's use of the Information. A person's review and/or reliance upon the Information is at their own risk. We are not responsible for omissions or errors in the Information. We will not update the Information and we are not responsible for actions taken by any person who relies upon the Information.
What do we urge potential investors to do?
Investors should conduct their own in-depth investigation of the Profiled Issuers with the assistance of his or her legal, tax and investment advisors. An investor's review of the Information should include but not be limited to the Profiled Issuer's financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer's business and other information you and your advisors deem material to an investment decision. An investor's review should include, but not be limited to a review of available public sources and information you receive directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
Why is this Disclaimer being provided?
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 ( the "Exchange Act") and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended ("the "Securities Act"), to specifically disclose our compensation to you as well as other information including that we may hold, as well as purchase and sell the securities of a Profiled Issuer before, during and after we publish the Information about the Profiled Issuer. We may instruct investors to purchase the securities of a Profiled Issuer during the same time that we sell.
The anti-fraud provisions of state and federal securities laws require us to inform you that we will engage in buying and selling of Profiled Issuer's securities before, during and after the Campaigns.
What we are not.
We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
An independent advisor or consultant;
Providing investment advice;
Acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
Broker-dealer activities or acting in the capacity of a registered representative or broker;
Stock picker;
Securities trading expert;
Securities researcher or analyst;
Financial planner or financial planning;
Provider of stock recommendations;
Provider of advice about buy and sell or hold recommendations as to specific securities; or
Making an offer or sale of securities or solicitation to purchase securities.
What conflicts of interest do we have in publishing the Information?
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
We do not publish any negative information whatsoever about the Profiled Issuers;
We may own a Profiled Issuer's securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer's securities will likely cause investors to suffer losses;
A short time after we acquire a Profiled Issuer's securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer's securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
Parties holding a Profiled Issuer's securities including those who engage our services and/or compensate us will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
What are some of the risks that investors should be aware of?
Any investment in the Profiled Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers includes, but is not limited to the risks stated below.
The Information is not a solicitation or recommendation to buy, sell or hold securities and we do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements that a Profiled Issuer's stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer's future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information is material or non-material making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
When the Campaign ends, the securities of a Profiled Issuer will decline dramatically.
If the Information states that a Profiled Issuer's securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative ; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information contains forward looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made and we do not undertake to update forward looking statements that may change at any time.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com (See section below titled Risks Related to the Profiled Issuers, which provides additional information pertaining thereto).
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer even where such compensation is not disclosed by them.
By reading the Information you agree to indemnify and hold us harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information.
Risks Related to the Profiled Issuers
We do not provide you with all of the risks related to the Profiled Issuers and to understand such risks you must conduct your own due diligence with the assistance of your legal, tax and investment advisor.
Any investment in a Profiled Issuer's securities is high risk. If you invest in the securities of a Profiled Issuer you could lose your entire investment.
The continued operations and future prospects of a Profiled Issuer may be dependent upon receiving adequate financing which they may be unable to obtain.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or OTC Market's Pink Sheet quoted company may be delinquent in its Pink Sheet reporting obligations as reported by the OTC Markets News Service's or OTC Markets posting a negative sign pertaining to the Profiled Issuer at www.pinksheets.com, as follows: (i) Limited Information for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) Pink Sheets – No Information, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) Caveat Emptor, signifying Buyer Beware that there is a public interest concern associated with a company's illegal spam campaign, questionable stock promotion, known investigation of a company's fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
Often the Profiled Issuers are development stage companies with little or no operations, and their securities should be considered extremely speculative for investment purposes.
The Profiled Issuers are negatively affected by the current economic downturn and may have a lack of adequate financing to meet their operating expenses, operational goals and expansion plans.
The Profiled Issuers may have inadequate financing to pursue their operational plans and support their ongoing operations.
Risks Related to buying the securities of the Profiled Issuers
The Information may recommend that investors purchase a Profiled Issuer's shares while we sell securities of the same Profiled Issuer which will likely cause investors to suffer losses.
We may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
The Information may instruct investors to buy a Profiled Issuer's securities so that the person who hires and compensates us can sell their own shares which may cause you to suffer a loss of part or all of your investment.
When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer's securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer's securities; (c) if selling, cause the Profiled Issuer's stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
Are risks in this disclaimer the only risks investors should be aware of?
No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax adviser prior to purchasing the securities of any Profiled Issuer.
COMPENSATION DISCLAIMER
Pursuant to an agreement between Midam Ventures LLC and RosCan Gold Corporation (ROS.V), Midam has been paid $100,000 by RosCan Gold Corporation (ROS.V) for a period from July 1, 2019 to November 1, 2019. We may buy or sell additional shares of RosCan Gold Corporation (ROS.V) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about RosCan Gold Corporation (ROS.V).
Pursuant to an agreement between Midam Ventures LLC and Global Consortium Inc. (GCGX), Midam has been paid $20,000 from Global Consortium Inc. (GCGX) for a period from January 22, 2019 to February 22, 2019. Midam has been paid $20,000 by a 3rd Party, VS Services LLC for a period of coverage on Global Consortium Inc. (GCGX) from February 26, 2019 to March 26, 2019. We may buy or sell additional shares of (GCGX) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Global Consortium Inc. (GCGX).
Pursuant to an agreement between Midam Ventures LLC and Nabis Holdings (OTC:INNPF) (CSE:NAB), Midam has been paid $250,000 by Nabis Holdings (OTC:INNPF) (CSE:NAB) for a period from January 22, 2019 to April 22, 2019. We may buy or sell additional shares of (OTC:INNPF) (CSE:NAB) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Nabis Holdings (OTC:INNPF) (CSE:NAB).
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018, and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam has been compensated an additional $100,000 by Leafbuyer Technologies for a period of coverage from April 12, 2019 to June 12, 2019. We owned 77,000 shares of Leafbuyer Technologies. We may buy or sell additional shares of (LBUY) in the open market at any time (as of 3/29/2019) Midam Ventures no longer owns 77,000 shares of LBUY), including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc.
Pursuant to an agreement between Midam Ventures LLC and TransCanna (TCAN.CN), Midam is being paid $33,000 per month for 3 months by TransCanna (TCAN.CN) for a period from February 14, 2019 to May 14, 2019. We may buy or sell additional shares of (TCAN.CN) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about TransCanna (TCAN.CN).
Pursuant to an agreement between Midam Ventures LLC and Integrated Cannabis Solutions, Inc. (IGPK), Midam has been paid $20,000 from Integrated Cannabis Solutions, Inc. (IGPK) for a period from February 20, 2019 to March 20, 2019. We may buy or sell additional shares of (IGPK) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Integrated Cannabis Solutions, Inc. (IGPK).
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Ionic Brands Corp (IONC), Midam has been paid $50,000 from Ionic Brands Corp (IONC) for a period from April 2, 2019 to May 2, 2019. Midam has been compensated an additional $150,000 from Ionic Brands for a period beginning July 22, 2019, and ending August 22, 2019. We may buy or sell additional shares of (IONC) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Ionic Brands Corp (IONC).
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Innovative Properties Inc dba Nabis Holdings, Midam has been paid $500,000 from Innovative Properties Inc dba Nabis Holdings for a period from 4/10/2019 to 7/25/2019. Midam has been compensated an additional $400,000 and 200,000 common restricted shares of Nabis Holdings to extend coverage an additional 6 months ending 1/25/2020. We may buy or sell additional shares of Innovative Properties Inc dba Nabis Holdings in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Innovative Properties Inc dba Nabis Holdings
Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 04/15/2018 – 5/15/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter now extended through June 21, 2019. We were paid $350,000 (CASH) for & were paid "0" shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Pursuant to an agreement between MIDAM VENTURES, LLC and a third party, Data Marketing Solutions Inc., Midam was hired for a period from 04/22/2018 – 5/22/2019 to publicly disseminate information about Driven Deliveries Inc. including on the Website and other media including Facebook and Twitter. We were paid $50,000 (CASH) for & were paid "0" shares of restricted common shares. Midam has been paid an additional $50,000 and extended its contract to 6/15/2019. Midam has been paid an additional $50,000 and extended its contract to 7/15/2019. We may buy or sell additional shares of Driven Deliveries Inc. Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Pursuant to an agreement between Midam Ventures LLC and IR Media Services, Midam has been paid $15,000 to market Choom Holdings for a period from 4/30/2019 to 5/30/2019. We may buy or sell additional shares of Choom Holdings in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Choom Holdings.
Pursuant to an agreement between Midam Ventures LLC and CLS Holdings USA Inc. (CLSH), Midam has been paid $200,000 from CLS Holdings USA Inc. (CLSH) for a period fromApril 26, 2019, (NOW EXTENDED TO) to July 26, 2019. We may buy or sell additional shares of (CLSH) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about CLS Holdings USA Inc. (CLSH).
Pursuant to an agreement between Midam Ventures LLC and Agraflora Organics International Inc. (CSE: AGRA) (OTC: PUFXF), Midam is being paid $25,000 per month by Agraflora Organics International Inc. (CSE: AGRA) (OTC: PUFXF) for 6 months during a period of coverage from May 6, 2019 to November 6, 2019. We may buy or sell additional shares of (CSE: AGRA) (OTC: PUFXF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Agraflora Organics International Inc. (CSE: AGRA) (OTC: PUFXF).
Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma (GTBP) including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "0" shares of restricted common shares. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid "0" shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Pursuant to an agreement between Midam Ventures LLC and AMWPR INC., Midam is being paid $105,000 for coverage on SOL Global Investments Corp, for a period from August 1, 2019 to November 1, 2019. As of July 25, 2019, we have been paid $50,000. We may buy or sell additional shares of (CSE: SOL) (OTC: SOLCF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about SOL Global Investments Corp. (CSE: SOL) (OTC: SOLCF).
Pursuant to an agreement between Midam Ventures LLC and 1933 Industries Inc. (TGIFF) (TGIF), Midam is being paid $25,000 a month for coverage on 1933 Industries Inc. (TGIFF) (TGIF), for a period from August 1, 2019 to February 1, 2019. As of August 1, 2019, we have been paid $50,000. We may buy or sell additional shares of 1933 Industries Inc. (TGIFF) (TGIF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about 1933 Industries Inc. (TGIFF) (TGIF).
Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid "0" shares of restricted common shares. We were paid $75,000 (CASH) by Liberty Defense Holdings AND HAVE EXTENDED coverage for a period from 11/1/2019 – 11/30/2019. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Pursuant to an agreement between Midam Ventures LLC and Integrated Cannabis Company (ICNAF) (ICAN), Midam is being paid $50,000 a month for coverage on Integrated Cannabis Company (ICNAF) (ICAN), for a period from August 19, 2019 to February 19, 2020. Midam Ventures LLC will also receive 150,000 common restricted shares of Integrated Cannabis Company (ICNAF) (ICAN) upfront and another 150,000 common restricted shares in 90 days. We may buy or sell additional shares of Integrated Cannabis Company (ICNAF) (ICAN) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Integrated Cannabis Company (ICNAF) (ICAN).
Pursuant to an agreement between Midam Ventures LLC and Tiziana Life Sciences plc (TLSA), Midam has been paid $150,000 by Tiziana Life Sciences plc (TLSA) for a period from August 22, 2019 to September 22, 2019. We may buy or sell additional shares of Tiziana Life Sciences plc (TLSA) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Tiziana Life Sciences plc (TLSA).
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $15,000 per month for 6 months by GT Biopharma (GTBP) for a period from September 4, 2019 to March 4, 2020. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 11, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF).
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $144,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019 and has been extended to January 31, 2020. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL).
Pursuant to an agreement between Midam Ventures LLC and IMC International (IMCX), Midam has been paid $200,000 for a period from November 26, 2019, to January 7, 2020. We may buy or sell additional shares of IMC International (IMCX) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about IMC International (IMCX).
Pursuant to an agreement between Midam Ventures LLC and 4Front Ventures Corp (FFNT)(FFNTF), Midam is being paid $20,000 for coverage on 4Front Ventures Corp (FFNT)(FFNTF), for a period from November 27, 2019 to January 7, 2020. We may buy or sell additional shares of 4Front Ventures Corp (FFNT)(FFNTF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about 4Front Ventures Corp (FFNT)(FFNTF).
Pursuant to an agreement between MIDAM VENTURES, LLC and Leafbuyer Technologies, Inc, we were hired for a period from 2/2/2018 – 5/2/2018 NOW EXTENDED TO 10/2/2018 to publicly disseminate information about (LBUY) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for & were paid "77,000" shares of restricted common shares. We own zero shares of (LBUY), which we purchased in the open market. Once the (6) Six month restriction is complete on 8/2/2018 we plan to sell the "77,000" shares of (LBUY) that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Midam Ventures, LLC has been compensated $100,000.00 by Ellis Stewart, LLC for a period beginning October 1, 2017 and ending November. 1, 2017 & Midam Ventures, LLC has been compensated an additional $150,000.00 by Ellis Stewart, LLC for a period beginning November 1, 2017 and ending December. 1, 2017 & Midam Ventures, LLC has been compensated an additional $150,000.00 by Ellis Stewart, LLC for a period beginning December 1, 2017 and ending December 31, 2017 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Midam Ventures, LLC has been compensated an additional $250,000.00 by Ellis Stewart, LLC for a period beginning January 1, 2018 and ending February 1, 2018 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Midam Ventures, LLC has been compensated an additional $100,000.00 by Ellis Stewart, LLC for a period beginning February 26, 2018 and ending March 30, 2018 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.
Midam Ventures, LLC has been compensated $400,000.00 by a non affiliate 3rd party Hilton Capital Inc & $100,000.00 by Graphite Energy Corp. beginning January 16, 2018 and ending February 16, 2017, which has been extended to March 26, 2018 for an additional $150,000 by a non affiliate 3rd Party Hilton Capital Inc. to publicly disseminate information about Graphite Energy Corp. We may buy or sell additional shares of Graphite Energy Corp in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.
Midam Ventures, LLC has been compensated $100,000.00 by a non affiliate third party for a period beginning October 20, 2017 and ending November 20, 2017, which has been extended through March 31, 2018 for an additional total of $300,000 by a non affiliate third party to publicly disseminate information about (BLKCF). We may buy or sell additional shares of (BLKCF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.
MIDAM VENTURES LLC. has been compensated $2,100,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending June 15, 2018 to publicly disseminate information about (GTBP).to publicly disseminate information about (GTBP). We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.
Midam Ventures was paid an advertising fee of $120,000 cash from a non-affiliate 3rd party for visual sponsorship and visual placement of Platinum Pari-mutuel Holdings, Inc. (PPMH) within written materials FOR A DURATION OF 30 DAYS Beginning 01/25/2017 & ending 02/25/2017
MIDAM VENTURES, LLC was paid an advertising fee of $50,000 cash & ZERO Restricted Common shares by HLT Products an affiliate company of Ubiquitech Software Corp. for visual sponsorship and for visual placement of Ubiqutech Software Corp (UBQU) within written materials. FOR A Period Beginning 02/21/2017 & ending 03/24/2017.
MIDAM VENTURES LLC was paid an advertising fee of $65,000 cash & ZERO Restricted Common shares by JOEY New York (JOEY). For visual sponsorship and for visual placement of JOEY New York (JOEY) within written materials. FOR A Period Beginning 07/31/2017 & ending 08/31/2017.
MIDAM VENTURES LLC was paid an advertising fee of $150,000 cash & ZERO Restricted Common shares by A NON-AFFILIATE 3RD PARTY. For visual sponsorship and for visual placement of (MEDD) within written materials. FOR A Period Beginning 08/8/2017 & ending 09/7/2017.
MIDAM VENTURES LLC was paid an advertising fee of $150,000 cash & ZERO Restricted Common shares by Pacific Rim Cobalt for visual sponsorship and for visual placement of (PCRCF) within written materials FOR A Period Beginning 06/27/2018 & ending 08/17/2018.
MIDAM VENTURES LLC was paid an advertising fee of $200,000 cash & ZERO Restricted Common shares by Marapharm Ventures, Inc. for visual sponsorship and for visual placement of (MRPHF) within written materials FOR A Period Beginning 06/27/2018 & ending 07/27/2018.
MIDAM VENTURES LLC is being paid an advertising fee of $63,333 cash per month & ZERO Restricted Common shares by GTEC Holdings, Inc. for visual sponsorship and for visual placement of (GTEC) within written materials FOR A Period Beginning 07/10/2018 & ending 07/10/2019.
MIDAM VENTURES LLC is being paid an advertising fee of $200,000 cash per month & ZERO Restricted Common shares by Beleave Inc. for visual sponsorship and for visual placement of (BLEVF) within written materials FOR A Period Beginning June 18, 2018 and ending July 31, 2018 NOW EXTENDED TO 8/31/2018.
MIDAM VENTURES LLC is being paid an advertising fee of $200,000 cash per month & ZERO Restricted Common shares by Marapharm Ventures for visual sponsorship and for visual placement of (MRPHF) within written materials FOR A Period Beginning June 27, 2018 and ending July 27, 2018 NOW EXTENDED TO 8/17/2018.
Pursuant to an agreement between Midam Ventures and Millennial ESports Corp, Midam has been paid $150,000 from the company and ZERO shares of Millennial ESports Corp for a duration of 3 months beginning May 8, 2018, and ending August 22, 2018 now extended through November 1, 2018. We may buy or sell additional shares of (MLLLF/GAME) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information about Millennial ESports Corp.
MIDAM VENTURES LLC is being paid an advertising fee of $200,000 cash per month & ZERO Restricted Common shares by GT Biopharma, Inc. for visual sponsorship and for visual placement of (GTBP) within written materials FOR A Period Beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018.
MIDAM VENTURES LLC is being paid an advertising fee of $25,000 cash & ZERO Restricted Common shares by Esta Global Communications for visual sponsorship and for visual placement of (NDVN) within written materials for a period from 7/30/2018 – 9/6/2018.
Midam has been paid $80,000 from Choom Holdings and 200,000 restricted common shares of Choom Holdings for a duration of 4 months beginning May 14, 2018 and ending September 14, 2018. We may buy or sell additional shares of (CHOOF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MIDAM VENTURES LLC is being paid an advertising fee of $25,000 cash & ZERO Restricted Common shares per month by Integrated Cannabis Company for visual sponsorship and for visual placement of (ICNAF/ICAN) within written materials for a period from 9/4/2018 – 3/9/2019. An affiliate of Midam Ventures, MAPH Enterprises LLC., a Florida Corporation was previously compensated $100,000 by a non-affiliate 3rd party for a 1 year period beginning August 1, 2017 and ending August 1, 2018 to publicly disseminate information about CNRP Mining, Inc. (CND.CN) (CRPGF) that is now Integrated Cannabis Company.
MIDAM VENTURES LLC is being paid a total advertising fee of $90,000 cash & ZERO Restricted Common shares by Pure Global Cannabis for visual sponsorship and for visual placement of (PRCNF) within written materials for a period from 7/23/2018 – 10/23/2018.
MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.
MIDAM VENTURES LLC is being paid a total advertising fee of $50,000 cash & ZERO Restricted Common shares by Leafbuyer Technologies for visual sponsorship and for visual placement of (LBUY) within written materials for a period from 9/24/2018 – 10/24/2018. We own 77,000 shares of Leafbuyer Technologies.
MIDAM VENTURES LLC is being paid a total advertising fee of $240,000 cash & ZERO Restricted Common shares by Biome Grow for visual sponsorship and for visual placement of (Biome Grow) within written materials for a period from October 1, 2018, and ending on October 1, 2019. We own 0 shares of Biome Grow.
Pursuant to an agreement between Midam Ventures LLC and Next Green Wave (NGW), Midam has been paid $150,000 from Next Green Wave (NGW) for a period from October 1, 2018 to November 8, 2018. Midam has been compensated an additional $100,000 and has extended its period of coverage to December 8, 2018. Midam has been compensated an additional $75,000 and has extended its period of coverage to January 8, 2019. Midam has been compensated an additional $50,000 and has extended its period of coverage to February 8, 2019. Midam has been compensated an additional $100,000 and has extended its period of coverage to April 12, 2019. We may buy or sell additional shares of (NGW) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Next Green Wave.
Pursuant to an agreement between Midam Ventures LLC and Koios Beverage Corp. (KBEVF), Midam has been paid $75,000 from Koios Beverage Corp. (KBEVF) for a period from October 25, 2018 to December 27, 2018. We may buy or sell additional shares of (KBEVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Koios Beverage Corp. (KBEVF).
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Pursuant to an agreement between Midam Ventures LLC and ICC International Cannabis Corp. (WRLD.CN) (KNHBF). Midam is being paid $150,000 for a period of 30 days beginning October 25, 2018 and ending November 25, 2018. We own 0 shares of ICC International Cannabis Corp. (WRLD.CN)(KNHBF). We may buy or sell additional shares of(WRLD.CN)(KNHBF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about ICC International Cannabis Corp. (WRLD.CN)(KNHBF).
Pursuant to an agreement between Midam Ventures LLC and CLS Holdings USA Inc. (CLSH), Midam has been paid $100,000 from CLS Holdings USA Inc. (CLSH) for a period from November 30, 2018 to December 30, 2018. We have been compensated an additional $100,000 (CASH) from CLS Holdings USA extending the contract another 30 days ending January 31, 2019. We have been compensated an additional $100,000 (CASH) from CLS Holdings USA extending the contract another 30 days ending February 28, 2019. We may buy or sell additional shares of (CLSH) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about CLS Holdings USA Inc. (CLSH).
Pursuant to an agreement between Midam Ventures LLC and Alkaline Water Company (WTER), Midam has been paid $50,000 from Alkaline Water Company (WTER) for a period from December 17, 2018 to January 17, 2019. We may buy or sell additional shares of (WTER) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information aboutAlkaline Water Company (WTER).
Pursuant to an agreement between Midam Ventures LLC and American Premium Water Corporation (HIPH), Midam has been paid $20,000 from American Premium Water Corporation (HIPH) for a period from December 21, 2018 to January 21, 2019. We may buy or sell additional shares of (HIPH) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about American Premium Water Corporation (HIPH).
MIDAM Ventures, LLC was paid an advertising fee of $60,000 cash & 10 Million Restricted Common shares by FBEC Worldwide Inc. (FBEC) for visual sponsorship of and for visual placement FBEC Worldwide Inc. (FBEC) within written materials. FOR A DURATION OF 1 YEAR BEGINNING JUNE 2015 ending JUNE 2016
MIDAM VENTURES, LLC was paid an advertising fee of $225,000 cash & ZERO Restricted Common shares by Life Clips, Inc. (LCLP) for visual sponsorship of TechStockInsider.com and for visual placement Life Clips, Inc. (LCLP) within written materials. FOR A DURATION OF 120 DAYS Beginning 5/4/2016. & ending 8/1/2016
MIDAM VENTURES, LLC was paid an advertising fee of 0 (zero) cash & 500,000 Restricted Common shares by Life Clips, Inc. (LCLP) for visual sponsorship of TechStockInsider.com and for visual placement Life Clips, Inc. (LCLP) within written materials. FOR A DURATION OF 90 DAYS Beginning 8/9/2016. & ending 11/9/2016
MIDAM VENTURES, LLC was paid an advertising fee of $105,000 cash & 21,125,000 Restricted Common shares by Progressive Care, Inc (RXMD) of which 10,000,000 are freely trade-able as of 7/18/2016 for marketing & awareness within written, social & display materials for Progressive Care, Inc (RXMD). FOR A DURATION OF 1 year and 6 months DAYS Beginning 6/11/2015. & ending 10/1/2016.
MIDAM VENTURES, LLC was paid an advertising fee of $75,000 cash & ZERO Restricted Common shares by iDdriven Inc. (IDDR) for visual sponsorship of TechStockInsider.com and for visual placement iDdriven Inc. (IDDR) within written materials. FOR A DURATION OF 60 DAYS Beginning 6/8/2016. & ending 8/8/2016
MIDAM VENTURES, LLC was paid an advertising fee of $150,000 cash & ZERO Restricted Common shares by EXOLifestyle, Inc. (EXOL) for visual sponsorship and for visual placement EXOLifestyle, Inc. (EXOL) within written materials. FOR A DURATION OF 30 DAYS Beginning 10/17/2016 & ending 11/17/2016.
MIDAM VENTURES, LLC was paid an advertising fee of $150,000 cash & ZERO Restricted Common shares by Heritage Printing, Corp. (HAGE) for visual sponsorship and for visual placement Heritage Printing, Corp. (HAGE) within written materials. FOR A DURATION OF 30 DAYS Beginning 11/15/2016 & ending 12/15/2016.
MIDAM Inc. is the next generation of financial communication. We offer a full suite of services including IR, media marketing, content creation, advertising, and direct relationships with PR contacts that have afforded our clients the ability to have their corporate message reach beyond traditional channels.
MIDAM is focused on helping publicly traded...Read More
Midam Investor Relations
3b3b3b


Xerographic Systems launched In Cyprus in January 2016 the Xerox Versant 2100 Press at Kemanes Print Shop - one of the premier Digital Printing Companies in Cyprus. Xerox Versant 2100 Press delivers more productivity at higher speeds than any other device in its class. Featuring an average monthly production volume range of 75–250K, this press is well-suited to take on volumes of short-run work or long variable data runs. Offering more versatility for a range of applications, the device supports an impressive array of substrates, including linen, polyester, vinyl and magnet stock.


text:
Pietro Bertani (né à Nonantola, en Émilie-Romagne, alors dans les États pontificaux, le , et mort à Rome le ) est un cardinal italien du . Il est membre de l'ordre des dominicains.

Biographie

Il est le fils de Francesco Bertani et Bianca Calori. Il entre à l'ordre Dominicain à un jeune âge, étudiant sous l'ordre de Tommaso Badia.

Pietro Bertani est lecteur de théologie et est théologien du cardinal Ercole Gonzaga. En 1537 il est nommé évêque de Fano et il participe au concile de Trente en 1546-1547. Bertani exerce plusieurs missions diplomatiques pour le pape.

Il est créé cardinal par le pape Jules III lors du consistoire du . Le cardinal Poggio participe aux deux conclaves de 1555 (élection de Marcel II et Paul IV).

Voir aussi

Articles connexes
 Liste des cardinaux créés par Jules III
 Liste des évêques de Fano

Liens externes

  Fiche du cardinal sur le site de la Florida International University

Personnalité de la Renaissance
Évêque de Fano
Cardinal italien du XVIe siècle
Cardinal créé par Jules III
Naissance à Nonantola
Naissance dans les États pontificaux
Naissance en 1501
Décès à Bologne
Décès en mars 1558

redpajama_set_name: RedPajamaWikipedia


Does ATC recognise where I am in relation to the airport and give the vectors accordingly? I heard final turns of more than 30 degrees should be avoided so does ATC ensure turns are within 30 degrees?
Yes, you will receive previous vectors towards the airport when you will then be given vectors towards the runway of no more than 45 degrees (I've never had a higher degree vector than that). Generally, ATC provides quite shallow vectors to final.